Title |
Defining outcomes for beta cell replacement therapy: a work in progress
|
---|---|
Published in |
Diabetologia, March 2018
|
DOI | 10.1007/s00125-018-4588-0 |
Pubmed ID | |
Authors |
Lorenzo Piemonti, Eelco J. P. de Koning, Thierry Berney, Jon S. Odorico, James F. Markmann, Peter G. Stock, Michael R. Rickels |
Abstract |
Defined outcomes for beta cell replacement therapy in the treatment of diabetes are critically needed. Progress towards the clinical acceptance of pancreas and islet transplantation has been hampered by the lack of clear definitions of functional and efficacy outcomes, as well as a lack of consistently applied glycaemic control metrics, together with poor alignment with the field of artificial insulin delivery/artificial pancreas development. To address this problem, the International Pancreas & Islet Transplant Association (IPITA) collaborated with the European Pancreas and Islet Transplant Association (EPITA) to develop a consensus for a joint statement on the definition of function and failure of beta cell replacement therapies, which is summarised in this commentary. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 40% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 26 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 19% |
Student > Master | 4 | 15% |
Student > Ph. D. Student | 4 | 15% |
Student > Bachelor | 3 | 12% |
Other | 2 | 8% |
Other | 3 | 12% |
Unknown | 5 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 35% |
Biochemistry, Genetics and Molecular Biology | 6 | 23% |
Agricultural and Biological Sciences | 2 | 8% |
Nursing and Health Professions | 1 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Other | 1 | 4% |
Unknown | 6 | 23% |